Alien Registration- Stults, Hiram S. (Portland, Cumberland County)

https://digitalmaine.com/alien_docs/21324/thumbnail.jp

Letter from Hiram S. Davis and Hannah Davis to Lieutenant J. L. Ham, April 16, 1880

Letter from Hiram S. and Hannah Davis to Lieutenant J.L. Ham, April 16, 1880. These are two separate letters that were mailed together. Both Hiram and Hannah inquired of Ham if he knew William Davis, Hiram\u27s brother and Hannah\u27s son who was in the same prison camp at Salisbury, North Carolina around the same time and died in January of 1865. They provide unique commentary on Northern reactions to the Confederate treatment of Union prisoners and the bitter attitude still held nearly fifteen years after the war. Taken from the Paul W. Bean Collection, Box no. 279, f.62https://digitalcommons.library.umaine.edu/paul_bean_papers/1052/thumbnail.jp

Going beyond the disability-based morbidity definition in the compression of morbidity framework

Background: As originally proposed by Fries, conceptualizing morbidity solely through associated functional limitation/disability (FL/D) remains the most widely accepted metric to assess whether increases in longevity have been accompanied by a compression of morbidity. Objective: To propose a departure from a highly restrictive FL/D-based definition of “morbidity” to a broader view that considers the burden of chronic diseases even when no overt FL/D occur. Design: We outline three reasons why the current framework of compression of morbidity should be broadened to also consider morbidity to be present even when there are no overtly measurable FL/D. We discuss various scenarios of morbidity compression and morbidity expansion under this broader rubric of morbidity. Conclusion: The rationale to go beyond a purely FL/D-based definition of morbidity includes: (1) substantial damage from chronic disease that can develop prior to overt FL/D symptoms occurring; (2) multiple costs to the individual and society that extend beyond FL/D, including medication costs, health care visits, and opportunity costs of lifelong treatment; and (3) psychosocial and stress burden of being labeled as diseased and the consequence for overall well-being. Adopting this broader definition of morbidity suggests that increases in longevity have been possibly accompanied by an expansion of morbidity, in contrast to Fries’ original hypothesis that morbidity onset (based on only FL/D) would be delayed to a greater extent than increases in survival. There is an urgent need for better data and more research to document morbidity onset and its link with increases in longevity and assess the important question on whether populations while living longer are also healthier

Bond for Costs on Appeal, \u3cem\u3eTVA v. Hill et al\u3c/em\u3e, Civil Action No. 3-76-48

Bond for costs on appeal, in the case of TVA v. Hill et al, United States District Court for the Eastern District of Tennessee, Northern Divisio

Interfirm Structure and Buyer-Salesperson Behavior Impact on Relationship Outcomes

The individual level interaction between the buyer and salesperson can best be understood in the broader framework provided by the inter-firm relationship. Very little research has been conducted that examines both firm level and interpersonal level constructs in the context of business relationships. The primary purpose of this study is to design and test a theoretical model that examines the effect of inter-firm structure and buyer-salesperson behaviors on relationship outcomes. The results suggest that in established relationships, the external environment plays a role in determining the how buyer-seller firms structure their relationships. The way in which the relationship is structured plays an important role in determining how the buyer and salesperson interact. Both inter-firm structure and buyer-salesperson behaviors, in turn, influence buyer satisfaction

N-Benzoyl-N′,N′-dimethyl­thio­urea

In the title compound, C10H12N2OS, the amide NCO group is twisted relative to the thio­ureido SCN2 group, forming a dihedral angle of 55.3 (2)°. The crystal packing shows inter­molecular N—H⋯S and weak C—H⋯O inter­actions, the former giving rise to the formation of centrosymmetric R 2 2(8) dimers

Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas

Identification of novel prognostic biomarkers typically requires a large dataset which provides sufficient statistical power for discovery research. To this end, we took advantage of the high‐throughput data from The Cancer Genome Atlas (TCGA) to identify a set of prognostic biomarkers in head and neck squamous cell carcinomas (HNSCC) including oropharyngeal squamous cell carcinoma (OPSCC) and other subtypes. In this study, we analyzed miRNA‐seq data obtained from TCGA patients to identify prognostic biomarkers for OPSCC. The identified miRNAs were further tested with an independent cohort. miRNA‐seq data from TCGA was also analyzed to identify prognostic miRNAs in oral cavity squamous cell carcinoma (OSCC) and laryngeal squamous cell carcinoma (LSCC). Our study identified that miR‐193b‐3p and miR‐455‐5p were positively associated with survival, and miR‐92a‐3p and miR‐497‐5p were negatively associated with survival in OPSCC. A combined expression signature of these four miRNAs was prognostic of overall survival in OPSCC, and more importantly, this signature was validated in an independent OPSCC cohort. Furthermore, we identified four miRNAs each in OSCC and LSCC that were prognostic of survival, and combined signatures were specific for subtypes of HNSCC. A robust 4‐miRNA prognostic signature in OPSCC, as well as prognostic signatures in other subtypes of HNSCC, was developed using sequencing data from TCGA as the primary source. This demonstrates the power of using TCGA as a potential resource to develop prognostic tools for improving individualized patient care

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer

BACKGROUND: Local-regional failure (LF) for locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity/mortality. Postoperative radiotherapy (PORT) can reduce LF and may enhance overall survival (OS) but has no defined role. We hypothesized that the addition of PORT would improve OS in LABC in a large nationwide oncology database. METHODS: We identified ≥ pT3pN0-3M0 LABC patients in the National Cancer Database diagnosed 2004-2014 who underwent RC ± PORT. OS was calculated using Kaplan-Meier and Cox proportional hazards regression modeling was used to identify predictors of OS. Propensity matching was performed to match RC patients who received PORT vs those who did not. RESULTS: 15,124 RC patients were identified with 512 (3.3%) receiving PORT. Median OS was 20.0 months (95% CI, 18.2-21.8) for PORT vs 20.8 months (95% CI, 20.3-21.3) for no PORT (P = 0.178). In multivariable analysis, PORT was independently associated with improved OS: hazard ratio 0.87 (95% CI, 0.78-0.97); P = 0.008. A one-to-three propensity match yielded 1,858 patients (24.9% receiving PORT and 75.1% without). In the propensity-matched cohort, median OS was 19.8 months (95% CI, 18.0-21.6) for PORT vs 16.9 months (95% CI, 15.6-18.1) for no PORT (P = 0.030). In the propensity-matched cohort of urothelial carcinoma patients (N = 1,460), PORT was associated with improved OS for pT4, pN+, and positive margins (P \u3c 0.01 all). CONCLUSION: In this observational cohort, PORT was associated with improved OS in LABC. While the data should be interpreted cautiously, these results lend support to the use of PORT in selected patients with LABC, regardless of histology. Prospective trials of PORT are warranted

cis-Bis[N-(2-furoyl)-N′,N′-diphenyl­thio­ureato-κ2 O,S]nickel(II)

In the title compound, [Ni(C18H13N2O2S)2], the NiII atom is coordinated by the S and O atoms of two N-furoyl-N′,N′-diphenyl­thio­ureate ligands in a slightly distorted square-planar coordination geometry. The two O and two S atoms are cis to each other

Tris[N-(2-furoyl)-N,N′-diphenyl­thio­ureato-κ2 O,S]cobalt(III)

In the title compound, [Co(C18H13N2O2S)3], the CoIII atom is coordinated by the S and O atoms of three N-furoyl-N′,N′-diphenyl­thio­urea ligands in a slightly distorted octa­hedral geometry. The three O atoms are arranged fac, as are the three S atoms